2011 713447-3452. pubmed 21270108maley et al.page 19roylance r et al.

2004 643414-3427. pubmed 15150093maley et al.page 21sottoriva a et al.

2016 28373-382. pubmed 27121213maley et al.page 22mlecnik b et al.

2013 13800-812. pubmed 24132111maley et al.page 23swidsinski a et al.

2013 62707-724. pubmed 23681854maley et al.page 26prosperi mc et al.

at the end of this example sequence the tumour is in the most manageable least evolvable category type 3 in table 2. of course chemotherapy immunotherapy and targeted therapy may have different effects depending on the details of those therapies and their interaction with the clones in the tumour and their ecosystem.maley et al.page 31table 1measures and assays for the factors that go into the evo- and eco-indiceseco-index ecological index ef5 2-2-nitro-1-h-imidazol-1-yl-n-22333-pentafluoropropyl acetamide evo-index evolutionary index fish fluorescence in situ hybridization fst fixation index mri magnetic resonance imaging rna-seq rna sequencing rrna ribosomal rna pet ct positron emission tomography and computed tomography snp singe nucleotide polymorphism.maley et al.page 32an initial classification schemetable 2maley et al.page 33d diversity d genetic epigenetic or phenotypic change over time eco-index ecological index evo-index evolutionary index h hazards r resources.

2012 481306-313. pubmed 22258609vogelstein b et al.

pubmed 26618723wangsa d et al.

2016 13898-109. pubmed 26175310schwarz rf et al.

pubmed 25710373urbschat s et al.

2011 391601-1608. pubmed 21922133birkbak nj et al.

2011 202183-2194. pubmed 21784954maley cc et al.

pubmed 16565718merlo lm et al.

2010 31388-1397. pubmed 20947487martinez p et al.

pubmed 27538785lipinski ka et al.

